🌟 Cheerful News Daily

The FDA gave tentative approval to a generic twice-yearly HIV prevention shot that will cost $40 per person per year in 120 countries, about 16 months after the brand-name version was approved. Here is what the trials show, how the timeline shrank, and what still stands between approval and patients.

In a phase 3 trial of 1,137 people, a personalized mRNA vaccine added to pembrolizumab after melanoma surgery lowered the risk of recurrence or death by 42%. Here is what the trial shows, why the first six months looked the same, and what is still open.

In a randomized trial of 236 adults with Ph-positive acute lymphoblastic leukemia, a regimen with no chemotherapy had higher event-free survival at 24 months than imatinib plus chemotherapy, 86% against 67%. Here is what the trial shows, why overall survival differs by less, and what is still open.

Nine private funders announced the Species Recovery Alliance at COP17, committing more than $500 million over five years to species classed as extinct in the wild, critically endangered, or endangered. Here is what the pledge covers, how it sits beside total nature funding, and what the sources do not yet say.

MIT engineers used targeted nanoparticles to reprogram natural killer cells inside living mice, with no lab manufacturing step. The cells cleared lymphoma, sent 3 of 5 melanoma mice into remission, and healed liver damage in an autoimmune model. Here is what the mouse results show and what human trials still need to prove.

A University of Sydney review of more than 70 conservation success stories found three conditions they share, from coral reefs in Papua New Guinea to albatross in Tasmania. Here is what the review shows, and what it does not yet prove about repeating those successes.